GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (FRA:I5X) » Definitions » Cyclically Adjusted PS Ratio

Precigen (FRA:I5X) Cyclically Adjusted PS Ratio : 1.35 (As of May. 21, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Precigen Cyclically Adjusted PS Ratio?

As of today (2024-05-21), Precigen's current share price is €1.258. Precigen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.93. Precigen's Cyclically Adjusted PS Ratio for today is 1.35.

The historical rank and industry rank for Precigen's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:I5X' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.77   Med: 1.34   Max: 3.5
Current: 1.36

During the past years, Precigen's highest Cyclically Adjusted PS Ratio was 3.50. The lowest was 0.77. And the median was 1.34.

FRA:I5X's Cyclically Adjusted PS Ratio is ranked better than
81.85% of 507 companies
in the Biotechnology industry
Industry Median: 5.55 vs FRA:I5X: 1.36

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Precigen's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.004. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.93 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Precigen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Precigen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Cyclically Adjusted PS Ratio Chart

Precigen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.56 1.22 1.32

Precigen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 1.11 1.38 1.32 1.41

Competitive Comparison of Precigen's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Precigen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precigen's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precigen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Precigen's Cyclically Adjusted PS Ratio falls into.



Precigen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Precigen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.258/0.93
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precigen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Precigen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.004/131.7762*131.7762
=0.004

Current CPI (Mar. 2024) = 131.7762.

Precigen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.088 100.560 0.115
201409 0.165 100.428 0.217
201412 0.251 99.070 0.334
201503 0.289 99.621 0.382
201506 0.366 100.684 0.479
201509 0.424 100.392 0.557
201512 0.327 99.792 0.432
201603 0.334 100.470 0.438
201606 0.396 101.688 0.513
201609 0.369 101.861 0.477
201612 0.368 101.863 0.476
201703 0.422 102.862 0.541
201706 0.405 103.349 0.516
201709 0.320 104.136 0.405
201712 0.458 104.011 0.580
201803 0.252 105.290 0.315
201806 0.300 106.317 0.372
201809 0.215 106.507 0.266
201812 0.226 105.998 0.281
201903 0.131 107.251 0.161
201906 0.189 108.070 0.230
201909 0.107 108.329 0.130
201912 -0.181 108.420 -0.220
202003 0.168 108.902 0.203
202006 0.165 108.767 0.200
202009 0.121 109.815 0.145
202012 0.089 109.897 0.107
202103 0.106 111.754 0.125
202106 0.016 114.631 0.018
202109 0.014 115.734 0.016
202112 0.016 117.630 0.018
202203 0.025 121.301 0.027
202206 0.014 125.017 0.015
202209 0.084 125.227 0.088
202212 0.008 125.222 0.008
202303 0.008 127.348 0.008
202306 0.007 128.729 0.007
202309 0.005 129.860 0.005
202312 0.005 129.419 0.005
202403 0.004 131.776 0.004

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Precigen  (FRA:I5X) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Precigen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Precigen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Precigen (FRA:I5X) Business Description

Industry
Traded in Other Exchanges
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen (FRA:I5X) Headlines

No Headlines